Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The prognostic significance of e13a2 and b14a2 BCR/ABL1 transcripts in chronic myeloid leukaemia patients who switched to nilotinib after suboptimal response or failure on frontline imatinib therapy

Next Previous
Trial Profile

The prognostic significance of e13a2 and b14a2 BCR/ABL1 transcripts in chronic myeloid leukaemia patients who switched to nilotinib after suboptimal response or failure on frontline imatinib therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 24 Jul 2017 New trial record
  • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top